Proto-oncogene tyrosine-protein kinase Src

SRC
Available structures PDB Human UniProt search: PDBe RCSB List of PDB id codes 1A07, 1A08, 1A09, 1A1A, 1A1B, 1A1C, 1A1E, 1FMK, 1HCS, 1HCT, 1KSW, 1O41, 1O42, 1O43, 1O44, 1O45, 1O46, 1O47, 1O48, 1O49, 1O4A, 1O4B, 1O4C, 1O4D, 1O4E, 1O4F, 1O4G, 1O4H, 1O4I, 1O4J, 1O4K, 1O4L, 1O4M, 1O4N, 1O4O, 1O4P, 1O4Q, 1O4R, 1SHD, 1Y57, 1YI6, 1YOJ, 1YOL, 1YOM, 2BDF, 2H8H, 3VRO, 3ZMP, 3ZMQ, 4F59, 4F5A, 4F5B, 4HXJ, 4K11, 4MXO, 4MXX, 4MXY, 4MXZ
Identifiers
Aliases	SRC, ASV, SRC1, c-p60-Src, SRC proto-oncogene, non-receptor tyrosine kinase, THC6
External IDs	HomoloGene: 21120 GeneCards: SRC
Targeted by Drug
bosutinib, dasatinib anhydrous, saracatinib, SU6656[1]
Gene ontology Molecular function • ion channel binding • protein domain specific binding • protein complex binding • SH2 domain binding • kinase activity • protein C-terminus binding • receptor binding • estrogen receptor binding • ATP binding • protein kinase activity • insulin receptor binding • non-membrane spanning protein tyrosine kinase activity • kinase binding • heme binding • enzyme binding • transferase activity • ephrin receptor binding • scaffold protein binding • integrin binding • protein binding • protein tyrosine kinase activity • protein kinase binding • cell adhesion molecule binding • SH3/SH2 adaptor activity • protein kinase C binding • hormone receptor binding • nucleotide binding • growth factor receptor binding • phosphoprotein binding • cadherin binding involved in cell-cell adhesion Cellular component • cytoplasm • cytosol • membrane • extrinsic component of cytoplasmic side of plasma membrane • ruffle membrane • mitochondrion • perinuclear region of cytoplasm • caveola • neuron projection • cytoskeleton • nucleus • lysosome • extracellular exosome • late endosome • plasma membrane • actin filament • postsynaptic density • mitochondrial inner membrane • cell-cell adherens junction Biological process • response to mineralocorticoid • negative regulation of telomere maintenance via telomerase • response to interleukin-1 • positive regulation of MAP kinase activity • positive regulation of canonical Wnt signaling pathway • negative regulation of telomerase activity • cellular response to progesterone stimulus • regulation of intracellular estrogen receptor signaling pathway • stress fiber assembly • positive regulation of protein serine/threonine kinase activity • platelet activation • positive regulation of smooth muscle cell migration • protein phosphorylation • regulation of vascular permeability • vascular endothelial growth factor receptor signaling pathway • positive regulation of ERK1 and ERK2 cascade • regulation of podosome assembly • cell cycle • substrate adhesion-dependent cell spreading • osteoclast development • cell proliferation • transforming growth factor beta receptor signaling pathway • cellular response to hypoxia • cellular response to transforming growth factor beta stimulus • negative regulation of protein homooligomerization • positive regulation of protein kinase B signaling • positive regulation of lamellipodium morphogenesis • epidermal growth factor receptor signaling pathway • branching involved in mammary gland duct morphogenesis • Fc-gamma receptor signaling pathway involved in phagocytosis • negative regulation of intrinsic apoptotic signaling pathway • positive regulation of cytokine secretion • negative regulation of extrinsic apoptotic signaling pathway • response to mechanical stimulus • response to virus • positive regulation of epithelial cell migration • signal complex assembly • stimulatory C-type lectin receptor signaling pathway • positive regulation of platelet-derived growth factor receptor signaling pathway • oogenesis • positive regulation of transcription, DNA-templated • regulation of epithelial cell migration • response to nutrient levels • positive regulation of DNA biosynthetic process • cellular response to insulin stimulus • protein autophosphorylation • viral process • negative regulation of focal adhesion assembly • response to acidic pH • single organismal cell-cell adhesion • response to fatty acid • regulation of cell projection assembly • phosphorylation • immune system process • negative regulation of mitochondrial depolarization • positive regulation of integrin activation • negative regulation of apoptotic process • cellular response to platelet-derived growth factor stimulus • positive regulation of podosome assembly • positive regulation of glucose metabolic process • transcytosis • cellular response to fluid shear stress • response to electrical stimulus • positive regulation of protein transport • uterus development • protein destabilization • regulation of cell-cell adhesion • peptidyl-tyrosine autophosphorylation • integrin-mediated signaling pathway • positive regulation of insulin receptor signaling pathway • progesterone receptor signaling pathway • negative regulation of transcription, DNA-templated • adherens junction organization • negative regulation of anoikis • response to hydrogen peroxide • leukocyte migration • activation of protein kinase B activity • negative regulation of cysteine-type endopeptidase activity involved in apoptotic process • intracellular signal transduction • regulation of early endosome to late endosome transport • ephrin receptor signaling pathway • T cell costimulation • positive regulation of intracellular signal transduction • regulation of caveolin-mediated endocytosis • regulation of cell cycle • positive regulation of phosphatidylinositol 3-kinase activity • cellular response to reactive oxygen species • cellular response to peptide hormone stimulus • positive regulation of gene expression • cellular response to fatty acid • regulation of cell proliferation • angiotensin-activated signaling pathway involved in heart process • peptidyl-serine phosphorylation • positive regulation of protein autophosphorylation • positive regulation of cyclin-dependent protein serine/threonine kinase activity • positive regulation of apoptotic process • peptidyl-tyrosine phosphorylation • forebrain development • regulation of protein binding • cellular response to lipopolysaccharide • regulation of bone resorption • cell migration • response to drug • signal transduction • positive regulation of cell adhesion • cell adhesion • positive regulation of protein processing • innate immune response • positive regulation of peptidyl-tyrosine phosphorylation • neurotrophin TRK receptor signaling pathway • positive regulation of small GTPase mediated signal transduction • bone resorption • central nervous system development • positive regulation of protein localization to nucleus • platelet-derived growth factor receptor signaling pathway • ERBB2 signaling pathway • intracellular estrogen receptor signaling pathway Sources:Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	6714	n/a
Ensembl	ENSG00000197122	n/a
UniProt	P12931	n/a
RefSeq (mRNA)	NM_005417 NM_198291	n/a
RefSeq (protein)	NP_005408.1 NP_938033.1	n/a
Location (UCSC)	Chr 20: 37.34 – 37.41 Mb	n/a
PubMed search	[2]	n/a
Wikidata

View/Edit Human

View/Edit Mouse

Proto-oncogene tyrosine-protein kinase Src, also known as proto-oncogene c-Src or simply c-Src , is a non-receptor tyrosine kinase protein that in humans is encoded by the SRC gene. This protein phosphorylates specific tyrosine residues in other proteins. An elevated level of activity of c-Src tyrosine kinase is suggested to be linked to cancer progression by promoting other signals.^[3] c-Src includes an SH2 domain, an SH3 domain, and a tyrosine kinase domain.

c-Src stands for "cellular Src kinase" and should not be confused with "C-terminal Src kinase" (CSK) which is an enzyme which phosphorylates c-Src at its C-terminus and provides negative regulation of Src's enzymatic activity. c-Src is a widely studied member of non-receptor tyrosine kinases which are not associated with a cell-surface receptor.

Src (pronounced "sarc" as it is short for sarcoma) is a proto-oncogene encoding a tyrosine kinase originally discovered by J. Michael Bishop and Harold E. Varmus, for which they were awarded the 1989 Nobel Prize in Physiology or Medicine.^[4] It belongs to a family of non-receptor tyrosine kinases called Src family kinases.

This gene is similar to the v-Src gene of Rous sarcoma virus. This proto-oncogene may play a role in the regulation of embryonic development and cell growth. The protein encoded by this gene is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by CSK. Mutations in this gene could be involved in the malignant progression of colon cancer. Two transcript variants encoding the same protein have been found for this gene.^[5]

Discovery

In 1979, J. Michael Bishop and Harold E. Varmus discovered that normal chickens contain a gene that is structurally closely related to v-Src.^[6] The normal cellular gene was called c-src (cellular-src).^[7] This discovery changed the current thinking about cancer from a model wherein cancer is caused by a foreign substance (a viral gene) to one where a gene that is normally present in the cell can cause cancer. It is believed that at one point an ancestral virus mistakenly incorporated the c-Src gene of its cellular host. Eventually this normal gene mutated into an abnormally functioning oncogene within the Rous sarcoma virus. Once the oncogene is transfected back into a chicken, it can lead to cancer.

Structure and function

There are 9 members part of the Src family kinases: c-Src , Yes, Fyn, Fgr, Yrk, Lyn, Blk, Hck, and Lck.^[8] The expression of these Src family members are not the same throughout all tissues and cell types. Src, Fyn and Yes are expressed ubiquitously in all cell types while the others are generally found in hematopoietic cells.^{[9][10][11][12]}

c-Src is made up of 6 functional regions: Src homology (SH) 4 domain (SH4 domain), unique region, SH3 domain, SH2 domain, catalytic domain and short regulatory tail. When Src is inactive, the phosphorylated tyrosine group at the 527 position interacts with the SH2 domain which helps the SH3 domain interact with the flexible linker domain and thereby keeps the inactive unit tightly bound. The activation of c-Src causes the dephosphorylation of the tyrosine 527. This induces long-range allostery via protein domain dynamics, causing the structure to be destabilized, resulting in the opening up of the SH3, SH2 and kinase domains and the autophosphorylation of the residue tyrosine 416.^[13][14][15]

c-Src can be activated by many transmembrane proteins that include: adhesion receptors, receptor tyrosine kinases, G-protein coupled receptors and cytokine receptors. Most studies have looked at the receptor tyrosine kinases and examples of these are platelet derived growth factor receptor (PDGFR) pathway and epidermal growth factor receptor (EGFR). When src is activated, it promotes survival, angiogenesis, proliferation and invasion pathways. It also regulates angiogenic factors and vascular permeability after focal cerebral ischemia-reperfusion,^[16][17] and regulates matrix metalloproteinase-9 activity after intracerebral hemorrhage.^[18]

Src contains at least three flexible protein domains, which, in conjunction with myristoylation, can mediate attachment to membranes and determine subcellular localization.^[19]

Role in cancer

The activation of the c-Src pathway has been observed in about 50% of tumors from colon, liver, lung, breast and the pancreas.^[20] Since the activation of c-Src leads to the promotion of survival, angiogenesis, proliferation and invasion pathways, the aberrant growth of tumors in cancers is observed. A common mechanism is that there are genetic mutations that result in the increased activity or the overexpression of the c-Src leading to the constant activation of the c-Src.

Colon

The activity of c-Src has been best characterized in colon cancer. Researchers have shown that Src expression is 5 to 8 fold higher in premalignant polyps than normal mucosa.^[21][22][23] The elevated c-Src levels have also been shown to have a correlation with advanced stages of the tumor, size of tumor, and metastatic potential of tumors.^[24][25]

Breast

EGFR activates c-Src while EGF also increases the activity of c-Src. In addition, overexpression of c-Src increases the response of EGFR-mediated processes. So both EGFR and c-Src enhance the effects of one another. Elevated expression levels of c-Src were found in human breast cancer tissues compared to normal tissues.^[26][27][28]

Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2), also known as erbB2, is correlated with a worse prognosis for breast cancer.^[29][30] Thus, c-Src plays a key role in the tumor progression of breast cancers.

Prostate

Members of the Src family kinases Src, Lyn and Fgr are highly expressed in malignant prostate cells compared to normal prostate cells.^[31] When the primary prostate cells are treated with KRX-123, which is an inhibitor of Lyn, the cells in vitro were reduced in proliferation, migration and invasive potential.^[32] So the use of a tyrosine kinase inhibitor is a possible way of reducing the progression of prostate cancers.

As a drug target

A number of tyrosine kinase inhibitors that target c-Src tyrosine kinase (as well as related tyrosine kinases) have been developed for therapeutic use.^[33] One notable example is dasatinib which has been approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (PH+) acute lymphocytic leukemia (ALL).^[34] Dasatinib is also in clinical trials for the use in non-Hodgkin’s lymphoma, metastatic breast cancer and prostate cancer. Other tyrosine kinase inhibitor drugs that are in clinical trials include bosutinib,^[35] bafetinib, AZD-530, XLl-999, KX01 and XL228.^[3]

Interactions

Src (gene) has been shown to interact with the following signaling pathways:

Survival

• PI3K
• Akt
• IKK
• NFkB
• Caspase 9

Angiogenesis

• STAT3
• p38 MAPK
• VEGF
• IL-8

Proliferation

• Shc
• Grb2/SOS
• Ras
• Raf
• MEK1 / MEK2
• Erk1/2

Motility

• FAK
• p190Rho/GAP
• Paxillin
• p130CAS
• RhoA
• JNK
• c-jun
• MLCK
• Myosin

Additional images

Overview of signal transduction pathways involved in apoptosis.

l i p i d - b i n d i n g P h o s p h o s e r i n e P h o s p h o s e r i n e SH3 S p l i c i n g v a r i a n t SH2 V a r i a n t P h o s p h o t y r o s i n e h y d r o p h o b i c b i n d i n g p o c k e t V a r i a n t Tyrosine kinase A c t i v e s i t e S H 3 / S H 2 d o m a i n i n t e r f a c e A T P P r o t o n a c c e p t o r a c t i v a t i o n l o o p P h o s p h o t y r o s i n e S - n i t r o s o c y s t e i n e P h o s p h o t h r e o n i n e P h o s p h o t y r o s i n e P h o s p h o t y r o s i n e P S / P T / P S ( C D K 5 ) P h o s p h o t y r F A K 2 / a u t o s w a p p e d d i m e r / p e p t i d e b i n d a u t o i n h i b i t o r y p T y r Top row:    Beta-strand region    Hydrogen bonded turn    Helical region List of protein features site 2 2 lipid-binding site 17 17 Phosphoserine site 35 35 Phosphoserine site 69 69 Phosphoserine site 74 74 Phosphothreonine site 75 75 Phosphoserine; by CDK5 region 87 93 Beta-strand region region 88 143 SH3 site 88 88 swapped dimer interface [polypeptide binding] site 93 93 peptide ligand binding site [polypeptide binding] region 99 102 Beta-strand region region 110 114 Beta-strand region region 117 117 Splicing variant region 118 126 Beta-strand region region 127 129 Hydrogen bonded turn region 132 136 Beta-strand region region 137 139 Helical region region 140 142 Beta-strand region region 146 148 Helical region region 147 247 SH2 region 152 154 Beta-strand region site 158 158 autoinhibitory site [polypeptide binding] site 158 158 phosphotyrosine binding pocket [polypeptide binding] region 158 165 Helical region region 167 170 Beta-strand region region 174 179 Beta-strand region region 176 176 Variant region 181 183 Beta-strand region region 187 195 Beta-strand region site 187 187 Phosphotyrosine (By similarity) region 196 198 Hydrogen bonded turn region 199 209 Beta-strand region site 205 205 hydrophobic binding pocket [polypeptide binding] region 211 213 Beta-strand region region 215 218 Beta-strand region region 221 225 Beta-strand region region 226 233 Helical region region 237 237 Variant region 240 242 Beta-strand region region 256 259 Beta-strand region region 267 269 Helical region region 270 519 Tyrosine kinase region 270 278 Beta-strand region site 276 276 Active site (ATP binding) region 283 289 Beta-strand region site 290 290 SH3/SH2 domain interface [polypeptide binding] region 290 292 Hydrogen bonded turn region 293 299 Beta-strand region site 298 298 ATP region 302 304 Hydrogen bonded turn region 307 319 Helical region region 328 332 Beta-strand region region 334 336 Beta-strand region region 338 341 Beta-strand region region 349 353 Helical region region 355 358 Helical region region 363 382 Helical region site 389 389 Proton acceptor region 392 394 Helical region region 395 397 Beta-strand region region 399 401 Helical region region 403 405 Beta-strand region site 406 406 activation loop (A-loop) region 410 413 Helical region region 417 420 Helical region site 419 419 Phosphotyrosine; by autocatalysis; alternate site 419 419 Phosphotyrosine; by FAK2; alternate (By similarity) region 423 426 Hydrogen bonded turn region 429 431 Helical region region 434 439 Helical region site 439 439 Phosphotyrosine region 444 459 Helical region region 460 462 Hydrogen bonded turn region 471 479 Helical region region 492 501 Helical region site 501 501 S-nitrosocysteine (By similarity) region 506 508 Helical region site 511 511 Phosphothreonine region 512 520 Helical region region 521 523 Hydrogen bonded turn site 522 522 Phosphotyrosine site 530 530 Phosphotyrosine; by CSK

References

1. "Drugs that physically interact with Proto-oncogene tyrosine-protein kinase Src view/edit references on wikidata".
2. "Human PubMed Reference:".
3. Wheeler DL, Iida M, Dunn EF (July 2009). "The role of Src in solid tumors". Oncologist. 14 (7): 667–78. doi:10.1634/theoncologist.2009-0009. PMC 3303596. PMID 19581523.
4. "The Nobel Prize in Physiology or Medicine 1989: J. Michael Bishop, Harold E. Varmus". Nobelprize.org. 1989-10-09. for their discovery of 'the cellular origin of retroviral oncogenes'
5. "Entrez Gene: SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)".
6. Stehelin D, Fujita DJ, Padgett T, Varmus HE, Bishop JM. (1977). "Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization". Virology. 76 (2): 675–84. doi:10.1016/0042-6822(77)90250-1. PMID 190771.
7. Oppermann H, Levinson AD, Varmus HE, Levintow L, Bishop JM (April 1979). "Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src)". Proc. Natl. Acad. Sci. U.S.A. 76 (4): 1804–8. Bibcode:1979PNAS...76.1804O. doi:10.1073/pnas.76.4.1804. PMC 383480. PMID 221907.
8. Thomas SM, Brugge JS (1997). "Cellular functions regulated by Src family kinases". Annu. Rev. Cell Dev. Biol. 13: 513–609. doi:10.1146/annurev.cellbio.13.1.513. PMID 9442882.
9. Cance WG, Craven RJ, Bergman M, Xu L, Alitalo K, Liu ET (December 1994). "Rak, a novel nuclear tyrosine kinase expressed in epithelial cells". Cell Growth Differ. 5 (12): 1347–55. PMID 7696183.
10. Lee J, Wang Z, Luoh SM, Wood WI, Scadden DT (January 1994). "Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene". Gene. 138 (1–2): 247–51. doi:10.1016/0378-1119(94)90817-6. PMID 7510261.
11. Oberg-Welsh C, Welsh M (January 1995). "Cloning of BSK, a murine FRK homologue with a specific pattern of tissue distribution". Gene. 152 (2): 239–42. doi:10.1016/0378-1119(94)00718-8. PMID 7835707.
12. Thuveson M, Albrecht D, Zürcher G, Andres AC, Ziemiecki A (April 1995). "iyk, a novel intracellular protein tyrosine kinase differentially expressed in the mouse mammary gland and intestine". Biochem. Biophys. Res. Commun. 209 (2): 582–9. doi:10.1006/bbrc.1995.1540. PMID 7733928.
13. Cooper JA, Gould KL, Cartwright CA, Hunter T (March 1986). "Tyr527 is phosphorylated in pp60c-src: implications for regulation". Science. 231 (4744): 1431–4. Bibcode:1986Sci...231.1431C. doi:10.1126/science.2420005. PMID 2420005.
14. Okada M, Nakagawa H (December 1989). "A protein tyrosine kinase involved in regulation of pp60c-src function". J. Biol. Chem. 264 (35): 20886–93. PMID 2480346.
15. Nada S, Okada M, MacAuley A, Cooper JA, Nakagawa H (May 1991). "Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src". Nature. 351 (6321): 69–72. Bibcode:1991Natur.351...69N. doi:10.1038/351069a0. PMID 1709258.
16. Zan L, Wu H, Jiang J, Zhao S, Song Y, Teng G, Li H, Jia Y, Zhou M, Zhang X, Qi J, Wang J (2011). "Temporal profile of Src, SSeCKS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema.". Neurochem Int. 58 (8): 872–9. doi:10.1016/j.neuint.2011.02.014. PMC 3100427. PMID 21334414.
17. Zan L, Zhang X, Xi Y, Wu H, Song Y, Teng G, Li H, Qi J, Wang J (2013). "Src regulates angiogenic factors and vascular permeability after focal cerebral ischemia-reperfusion.". Neuroscience. 262 (3): 118–128. doi:10.1016/j.neuroscience.2013.12.060. PMC 3943922. PMID 24412374.
18. Zhao X, Wu T, Chang CF, et al. (2015). "Toxic role of prostaglandin E2 receptor EP1 after intracerebral hemorrhage in mice.". Brain Behav Immun. 46: 293–310. doi:10.1016/j.bbi.2015.02.011. PMID 25697396.
19. Kaplan, J. M.; Varmus, H. E.; Bishop, J. M. (1990). "The src protein contains multiple domains for specific attachment to membranes". Molecular and Cellular Biology. 10 (3): 1000–9. doi:10.1128/mcb.10.3.1000. PMC 360952. PMID 1689455.
20. Dehm SM, Bonham K (April 2004). "SRC gene expression in human cancer: the role of transcriptional activation". Biochem. Cell Biol. 82 (2): 263–74. doi:10.1139/o03-077. PMID 15060621.
21. Bolen JB, Rosen N, Israel MA (November 1985). "Increased pp60c-src tyrosyl kinase activity in human neuroblastomas is associated with amino-terminal tyrosine phosphorylation of the src gene product". Proc. Natl. Acad. Sci. U.S.A. 82 (21): 7275–9. Bibcode:1985PNAS...82.7275B. doi:10.1073/pnas.82.21.7275. PMC 390832. PMID 2414774.
22. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W (June 1989). "pp60c-src activation in human colon carcinoma". J. Clin. Invest. 83 (6): 2025–33. doi:10.1172/JCI114113. PMC 303927. PMID 2498394.
23. Talamonti MS, Roh MS, Curley SA, Gallick GE (January 1993). "Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer". J. Clin. Invest. 91 (1): 53–60. doi:10.1172/JCI116200. PMC 329994. PMID 7678609.
24. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE (January 2002). "Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis". Cancer. 94 (2): 344–51. doi:10.1002/cncr.10221. PMID 11900220.
25. Cartwright CA, Meisler AI, Eckhart W (January 1990). "Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis". Proc. Natl. Acad. Sci. U.S.A. 87 (2): 558–62. Bibcode:1990PNAS...87..558C. doi:10.1073/pnas.87.2.558. PMC 53304. PMID 2105487.
26. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE (September 1992). "Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product". Cancer Res. 52 (17): 4773–8. PMID 1380891.
27. Biscardi JS, Belsches AP, Parsons SJ (April 1998). "Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells". Mol. Carcinog. 21 (4): 261–72. doi:10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N. PMID 9585256.
28. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, Rijksen G (December 1996). "c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis". J. Pathol. 180 (4): 383–8. doi:10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N. PMID 9014858.
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (January 1987). "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene". Science. 235 (4785): 177–82. Bibcode:1987Sci...235..177S. doi:10.1126/science.3798106. PMID 3798106.
30. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (May 1989). "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer". Science. 244 (4905): 707–12. Bibcode:1989Sci...244..707S. doi:10.1126/science.2470152. PMID 2470152.
31. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R (October 2005). "Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells". Cancer Res. 65 (20): 9185–9. doi:10.1158/0008-5472.CAN-05-1731. PMID 16230377.
32. Chang YM, Bai L, Yang I (2002). "Survey of Src activity and Src-related growth and migration in prostate cancer lines". Proc Am Assoc Cancer Res. 62: 2505a.
33. Musumeci F, Schenone S, Brullo C, Botta M (April 2012). "An update on dual Src/Abl inhibitors". Future Med Chem. 4 (6): 799–822. doi:10.4155/fmc.12.29. PMID 22530642.
34. Breccia M, Salaroli A, Molica M, Alimena G (2013). "Systematic review of dasatinib in chronic myeloid leukemia". Onco Targets Ther. 6: 257–65. doi:10.2147/OTT.S35360. PMC 3615898. PMID 23569389.
35. Amsberg GK, Koschmieder S (2013). "Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia". Onco Targets Ther. 6: 99–106. doi:10.2147/OTT.S19901. PMC 3594007. PMID 23493838.

External links

• src Gene at the US National Library of Medicine Medical Subject Headings (MeSH)
• src-Family Kinases at the US National Library of Medicine Medical Subject Headings (MeSH)
• Proteopedia SRC - interactive 3D model of the structure of SRC
• Vega geneview
• Src Info with links in the Cell Migration Gateway